. although stem cells are ultimately responsible for maintaining the epidermis through combined self-renewal and generation of differentiated progeny, there is evidence that not all dividing cells within the epidermis are stem cells 4 . one widely accepted model is that the progeny of stem cells that are destined to differentiate undergo a limited number of rounds of division before the initiation of terminal differentiation. These stem-cell progeny are known as transit amplifying cells and can be identified in cultures of human epidermis because they form small, abortive colonies. Whether transit amplifying cells also exist in vivo has recently been questioned by lineage-tracing experiments that demonstrate that mouse IFE is maintained by a single population of cells 4 . an understanding of the pathways that regulate epidermal stem-cell renewal and differentiation is of considerable importance in cancer research. This is because non-melanoma skin cancer, comprising tumours that arise from epidermal keratinocytes, is the most common type of cancer in the world 5 . The two main forms of non-melanoma skin cancer are basal-cell carcinoma and squamous-cell carcinoma. Whereas mutation of components of the hedgehog pathway is a hallmark of basal-cell carcinoma, a wide variety of changes have been observed in squamous-cell carcinoma. one of these is MYC amplification, which has been found in 50% of squamous-cell carcinomas arising in patients who have undergone long-term immunosuppression following organ transplantation 5 .
MYc expression in the skin
In human IFE, mYc protein is predominantly expressed in the basal cell layers, with little detectable immunoreactivity in the terminally differentiating suprabasal layers 6 . This is consistent with studies of cultured human keratinocytes, which demonstrate downregulation of mYc during suspensioninduced terminal differentiation 7, 8 . In human hair follicles mYc protein is detected in the proliferative zone at the base of the follicle (bulb), the quiescent zone of stem cells in the bulge and the terminally differentiating matrix cells that lie above the bulb and give rise to the hair fibre 6, 9 .
In skin squamous-cell carcinomas, upregulated expression of mYc is observed throughout the tumour mass 10 .
MYc overexpression in keratinocytes
The effects of mYc on keratinocytes in culture have been studied using various approaches, including knockdown or overexpression in primary human or immortalized mouse cells. one of the tools that has proved useful is overexpression of mYc-Er, a chimeric protein in which the c terminus of mYc is fused to the ligand-binding domain of a mutant oestrogen receptor (Er). In cells expressing mYc-Er, mYc is only active when cells are exposed to 4-hydroxytamoxifen (4-ohT) 11 . Therefore, the timing and duration of activation can be precisely controlled.
many studies have demonstrated that mYc has a positive role in keratinocyte proliferation. Epidermal growth factor (EGF), which is a key keratinocyte mitogen, stimulates mYc expression through increased mYc promoter activity 12, 13 . reduced proliferation of primary human keratinocytes that results from overexpression of the EGFr (EGF receptor) antagonist lrIG1 (leucine-rich repeats and immunoglobulinlike domains-containing protein) results in reduced mYc expression 13 . Furthermore, activation of mYc-Er stimulates DNa synthesis, an effect that is attenuated by overexpression of lrIG1 (ReF. 13) or knockdown of mISu (mYc-induced SuN-domaincontaining protein; also known as NSuN2), which is a mYc target gene that encodes an rNa methyltransferase 14 . Transforming growth factor β (TGFβ) induces keratinocyte growth arrest and this can be blocked by overexpression of mYc 12, 15 . conversely, knockdown of mYc can inhibit keratinocyte proliferation 16 . Flying in the face of these studies is the observation that overexpression of wild-type mYc or activated mYc-Er by retroviral transduction of primary human keratinocytes stimulates terminal differentiation 17 . In these experiments, stem cells were distinguished from transit amplifying cells on the basis of high β1-integrin expression and high capacity for clonal growth. mYc expression did not completely inhibit proliferation, but over a period of several days there was an increase in the number of cells that expressed low levels of β 1 integrin and formed abortive colonies of terminally differentiated cells. a marked increase in the proportion of differentiated, involucrinpositive, cells was observed 5 days after 4-ohT activation of mYc-Er. In normal epidermis, involucrin is first expressed in the upper spinous layers; however, in culture, expression is initiated during the transition from basal to suprabasal layer 17 . There was also an increase in the proportion of cells in the G2-m phase of the cell cycle, which is a feature of keratinocytes undergoing terminal differentiation in culture 14, 17 . When mYcEr-transduced keratinocytes were FacS (fluorescent-activated cell sorting) sorted on the basis of high or low β 1 -integrin levels and plated at clonal density in the presence or absence of 4-ohT, mYc exerted a selective effect in depleting the high β 1 (putative stem cell) population. 
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Transit amplifying cell Quiescent Proliferating Commitment to terminal differentiation although at first sight the findings of Gandarillas and Watt 17 contradict the studies in which mYc stimulates keratinocyte proliferation, it is important to consider the context and time over which keratinocytes have been observed. The biological consequences of mYc overexpression can vary depending on the level at which mYc is overexpressed 18 . In addition, there are striking differences in the time course of the assays that have been used to examine proliferation. The growth curves that show reduction of proliferation have an end-point of 25 days 17 , whereas stimulation of proliferation is observed over a shorter period 14 . Furthermore, epidermal-reconstitution experiments using mYc activation in keratinocytes that are cultured at the air-liquid interface on a dermal substrate show consistent results in terms of the effect of mYc on keratinocyte differentiation. mYc induces premature differentiation, as demonstrated by increased numbers of cells initiating terminal differentiation in the basal layer, disorganization of the basal layer and abnormal accumulation of cells in the final stages of terminal differentiation 14, 17, 19 . one further aspect of the effects of mYc on keratinocytes in culture is that keratinocytes are highly resistant to mYc-induced apoptosis 17, 20 , although it can be induced in differentiating suprabasal keratinocytes that are cultured in medium containing a low serum concentration 21 . This might reflect the fact that there are many similarities between apoptosis and epidermal terminal differentiation, albeit that apoptosis is executed in a matter of hours, whereas terminal differentiation takes place over a period of weeks. Similarities include the induction of transglutaminase, regulation by the extracellular matrix and loss of the cell nucleus 20 .
To reconcile the findings that mYc can stimulate both proliferation and terminal differentiation, it has been proposed that mYc-induced differentiation is a fail-safe device that protects keratinocytes from uncontrolled proliferation 13 (FIG. 2) . The model is that, in vivo, stem cells are frequently in a quiescent, nondividing state 4 . Downregulation of the stem-cell marker lrIG1 is one mechanism by which stem cells can be stimulated to divide, as a result of increased EGFr signalling, extracellularsignal-regulated kinase (ErK)-mitogenactivated protein kinase (maPK) activation and mYc expression. mYc-induced terminal differentiation would serve to protect the epidermis from the potentially oncogenic effects of sustained mYc activation.
Modulating MYc activity in vivo although studies of cultured keratinocytes have been valuable in elucidating the pathways that regulate epidermal self-renewal and differentiation, they do have several limitations. The first of these is that true homeostasis, that is, a balance between self-renewal and terminal differentiation, cannot be maintained in culture. Second, at present it is only possible to examine differentiation along a single lineage, that of the IFE. Finally, it is not possible in culture to examine the complex and dynamic interplay between keratinocytes and other cell types within the skin.
To examine the effects of mYc on the epidermis in vivo, several different mouse models have been generated (TABLe 1) . Different promoters have been used to target different subpopulations of keratinocytes, namely basal (which includes the stem-cell compartment of IFE, sebaceous gland and hair follicle) and suprabasal (terminally differentiating) keratinocytes. Both mYc and mYc-Er have been overexpressed and, in addition, the effects of targeted deletion of mYc or the co-repressor mIZ1 (also known as ZBTB17 (zinc finger and BTB-domain-containing 17)), which contributes to mYc-dependent repression of gene expression 22 , have been examined. one of the first transgenic models of mYc overexpression in the epidermis involved targeting mYc-Er to the suprabasal, postmitotic cell layers using the involucrin promoter (Inv) 21 . This perturbs the differentiation programme, triggers differentiated cells to divide and leads to the development of benign tumours that resemble papillomas, or pre-malignant lesions that resemble actinic keratosis. The phenotype is entirely reversible on withdrawal of 4-ohT. Part of the phenotype is due to increased vascular endothelial growth factor (vEGF) production by transgene-positive keratinocytes, resulting in stimulation of angiogenesis 21, 23 . Telomerase activation is required to elicit the full hyperplastic response, as the skin lesions that are induced by Inv-mYc-Er activation are less severe in telomerase-deficient mice than in wild-type mice 24 . The mYc-induced lesions do not convert into malignant tumours because keratinocytes expressing the transgene are still capable of undergoing terminal differentiation, albeit with abnormal retention of nuclei in the cornified cells 21, 25 . other effects of prolonged activation of Inv-mYc-Er are deregulation of the hair-follicle growth cycle and sebaceous-gland enlargement 26 . mYc has also been overexpressed in vivo under the control of a fragment of the loricrin promoter that is functional in proliferating and suprabasal keratinocytes 27 . loricrin-driven overexpression of mYc induces epidermal thickening (hyperplasia) and accumulation of the anucleate, cornified cells at the final stage of terminal differentiation (hyperkeratosis). as in mice that express Inv-mYc-Er, suprabasal cells are recruited back into the cell cycle. a further finding is that the mice are resistant to uvB-induced apoptosis in the skin.
using the keratin-14 promoter to target the basal layer, constitutive overexpression of wild-type mYc and inducible mYc-Er expression has been studied 28, 29 . adult mice in which mYc is constitutively expressed gradually lose their hair and develop spontaneous wounds; this is associated with reduced expression of β 1 integrins 29 . Treatment of K14-mYc-Er mice with 4-ohT causes progressive and irreversible changes in adult epidermis. Proliferation is stimulated and there is an increase in the number of differentiated cell layers in the IFE, reflecting increased numbers of spinous, granular and cornified layers (FIG. 1b) . Sebaceous-gland differentiation is increased, both within the hair follicles (FIG. 1b) and in the IFE, and wound healing is impaired 28, [30] [31] [32] . one technique that is used to identify quiescent stem cells is to look for cells that, having incorporated a DNa label such as bromodeoxyuridine (Brdu) soon after birth, retain that label in the adult tissue 4 . Whereas activation of mYc leads to depletion of label-retaining cells in the IFE, as a consequence of cell division 29 , it does not deplete them in the bulge, at least at the time points that were examined 31 . In K14-mYc-Er mice activation of mYc by a single application of 4-ohT is as effective as continuous treatment in stimulating proliferation and differentiation along the epidermal and sebaceous lineages 28 . This is in contrast to the effects of activating mYc in the suprabasal epidermal layers, where the phenotype is completely reversed on cessation of 4-ohT treatment 21 . The observation that transient activation of mYc in the basal layer has long-term effects on the epidermis is consistent with the hypothesis that it triggers irreversible exit from the stem-cell compartment.
constitutive expression of mYc under the control of the K5 promoter, which targets essentially the same basal-layer cells as the K14 promoter, also results in increased proliferation and thickness of the IFE 33 . apoptosis is reported to be increased in this model; however, the apoptotic markers that were evaluated -TuNEl (terminal deoxynucleotidyl transferase biotin-duTP nick-end labelling) staining and caspase activation -are also markers of cells undergoing terminal differentiation 20 and there is general agreement that keratinocytes are highly resistant to mYc-induced apoptosis 20, 34 . one important difference between the K14-mYc-Er and K5-mYc mice is that the K5-mYc mice develop spontaneous tumours in the skin and oral epithelium 33 . The time of onset of tumour development ranges from 20 to 60 weeks. K14-mYc-Er mice have not been examined at such late time points after mYc activation and so it is unclear whether tumour development represents a discrepancy between the models, or whether it is a matter of timing. a further possibility is that acute mYc activation stimulates differentiation whereas chronic activation triggers tumour formation. mIZ1 is a zinc-finger transcription factor that negatively regulates cell proliferation through p15 and p21, and which binds mYc and can repress the expression of mYc target genes 22, 35 . mIZ1 also binds a number of additional proteins, including Bcl6 (B-cell lymphoma 6), the topoisomerase-II-binding protein ToPBP1, the ubiquitin ligase hEcTh9, and Smad protein complexes 22, 36 . conditional deletion of Miz1 by expression of K14-cre recombinase results in changes in the hair growth cycle, hair pigmentation and hair-follicle structure 35 . These mice also have areas of suprabasal proliferation in the IFE, particularly where the hair follicle and IFE become continuous. The consequences of Miz1 deletion therefore bear some similarities to mYc overexpression, in particular the increase in proliferation and complex effects on terminal differentiation.
So far there have been two reports of Myc deletion in the epidermis (TABLe 1) . In one, epidermal deletion of Myc by K5-cre results in impaired wound healing, thinning of the IFE and premature differentiation. Stem-cell self-renewal is also impaired, as measured by a reduction in the number of DNa-labelretaining cells 37 . The K5 and K14 promoters are active from mid-gestation and therefore some of the effects might be attributable to the activity of mYc before birth. In the second study Myc was selectively deleted in adult epidermis through 4-ohT activation of K5-cre-Er 38 . In this situation there are no abnormalities in the IFE, hair follicle or sebaceous gland; and there are no changes in proliferation or expression of differentiation markers. however, the mice are resistant to ras-induced carcinogenesis as a result of upregulation of cyclin-dependent kinase inhibitor p21 (cDKN1a) 38 . The resistance to tumour formation on deletion of Myc is consistent with the spontaneous tumour development in K5-mYc mice 33 . What remains to be discovered is whether loss of mYc is to some extent compensated for by expression of other Myc genes. Mycn, in particular, is known to be expressed in the epidermis and drives proliferation in response to Shh (sonic hedgehog) 39, 40 . From this survey of the various mouse models a number of conclusions can be drawn. The effect of overexpressing mYc depends on the cell layer in which mYc is expressed. Nevertheless, wherever mYc is activated there is increased proliferation, which might reflect recruitment of quiescent stem cells into the cycle or increased rounds of division within the transit-amplifying-cell compartment (FIGS 2,3), and disturbed differentiation. The effects of mYc are reversible in differentiated cells but not in the basal layer. Finally, there is a link with tumour formation in some but not all models.
Interpreting MYc using microarrays one interpretation of the K14-mYc-Er and K14-mYc phenotypes [28] [29] [30] is that when mYc is activated in epidermal stem cells proliferation is stimulated as cells exit the stem-cell compartment and undergo differentiation along the lineages of the IFE and sebaceous glands 28 (FIG. 3) . In order to investigate the mechanisms by which mYc exerts these effects, microarray analysis has been carried out on rNa isolated from the skin of K14-mYc-Er and control mice, each treated with 4-ohT for 0, 1 or 4 days 32 .
MISU and cell proliferation. The majority of upregulated genes in the data set are involved in cell growth and proliferation, as would be expected from the increased proliferation of epidermis in which mYc is activated, and in agreement with microarray data on the effects of mYc in a range of cell types 32 . one of the upregulated genes is Misu, which shows expression in all tissues analysed so far 14 . In normal epidermis Misu expression is restricted to a subpopulation of cells in the sebaceous gland and to the proliferative cells at the base of growing hair follicles. on activation of mYc in K14-mYc-Er transgenic mice, Misu is upregulated in all cell compartments within the epidermis. mISu is localized to the nucleolus in G1 cells and knockdown of Misu blocks mYc-induced nucleolar enlargement. mISu expression is upregulated and detected 
P e R S P e c t I v e S
RAC1-PAK2 LRIG1
throughout the nucleus in S phase cells; in G2 it is found in a punctate distribution within the cytoplasm; and at mitosis it decorates the spindle. This dynamic redistribution during the cell cycle might hint at additional functions for mISu. Knockdown of Misu has no effect on keratinocytes that are proliferating at a low rate in reconstituted epidermis. however, mISu is required for mYc-induced keratinocyte proliferation in culture (FIG. 3) . In addition, knockdown of Misu reduces the volume of tumours that are formed by human squamous-cell carcinoma cells in nude mice. mISu is upregulated in a range of human tumours and is a potential therapeutic target in cancers with high mYc activity 14 .
Decreased cell adhesion. Forty percent of the genes that are downregulated on activation of mYc in the skin of K14-mYc-Er transgenic mice encode cell adhesion and cytoskeleton proteins 32 . These include components of the actomyosin cytoskeleton and α 6 β 4 integrin, the laminin receptor that localizes to hemidesmosomes, which anchor basal keratinocytes to the underlying basement membrane (FIG. 4) . In striking validation of the microarray results, there is a marked reduction both in the number and size of hemidesmosomes in 4-ohTtreated K14-mYc-Er epidermis 32 (FIG. 4) .
By downregulating the expression of genes that are involved in cell adhesion, mYc activation inhibits cell-extracellular-matrix adhesion, cell spreading and cell motility in cultured keratinocytes and impairs epidermal wound healing in vivo 29, 32 . In agreement with these observations, cultured keratinocytes in which Myc has been deleted are more migratory than wild-type primary mouse keratinocytes 37 . When K14-mYc-Er mice are crossed with mice overexpressing the β 1 -integrin subunit under the control of the K14 promoter, in order to partially rescue the reduced extracellular-matrix adhesiveness that results from mYc activation, proliferation is still increased and the sebaceous glands still enlarge; however, there is normalization of the basal layer and rescue of the mYc-induced premature onset of IFE terminal differentiation 19 . Keratinocyte differentiation is known to be regulated by extracellular-matrix adhesion, with reduced integrin-mediated adhesion being a positive stimulus for terminal differentiation 41, 42 . mYc-mediated downregulation of cell-adhesion genes therefore provides an explanation for why mYc can stimulate keratinocyte differentiation. There is the direct effect of causing cells to detach from the basement membrane and the indirect effect of preventing cells from moving to a location where they would normally receive hair-differentiation stimuli. We therefore hypothesize that mYc stimulates exit from the stem-cell compartment by reducing adhesive interactions with the local microenvironment or niche.
how does mYc negatively regulate cell-adhesion genes? one important mechanism involves mYc binding to mIZ1 (ReF. 19) (FIG. 3) . mIZ1 positively regulates cell adhesion 22 , and cell-adhesion and cytoskeleton genes that are downregulated in keratinocytes expressing wild-type mYc are not downregulated in cells expressing a mYc mutant that cannot bind to mIZ1 (mYc v394D ) 19 . Expression of mYc v394D in primary human keratinocytes does not decrease their adhesive properties and premature onset of terminal differentiation does not occur 19 . mYc v394D -expressing keratinocytes show enhanced expression of several adhesion factors, such as integrins α 6 and β 1 , and chromatin immunoprecipitation assays have indicated that there is a direct binding of mIZ1 to the promoters of these genes 19 . a second pathway through which mYc is implicated in epidermal stem-cell adhesion is through interaction with PaK2 (p21-activated kinase 2), an effector of the small GTPase rac1 (ReFS 42, 43) (FIG. 5) . conditional deletion of Rac1 in mouse epidermis has yielded varying degrees of perturbation of epidermal homeostasis, ranging from massive and widespread depletion of stem cells to milder effects that are selective for the IFE or hair follicles 42, [44] [45] [46] . Deletion of Rac1 leads to transient activation of mYc, suggesting that rac1 might negatively regulate mYc. Downstream of rac1, PaK2 can directly phosphorylate mYc, preventing E-box binding and heterodimerization with its partner protein maX (mYcassociated factor X) 42, 43 . Expression of rac1 in primary human keratinocytes can overcome the decrease in clonal growth and stimulation of terminal differentiation that is induced by mYc activation. a mYc mutant that cannot be phosphorylated by PaK2 is insensitive to rac1 downregulation, and a mutant that mimics constitutive phosphorylation does not induce terminal differentiation 42 . Therefore, PaK2-mediated phosphorylation of mYc prevents mYcinduced downregulation of extracellularmatrix adhesion factors that allow exit from the stem-cell niche. The interplay between rac1 and mYc in epidermal stem cells and transit amplifying cells is illustrated schematically in FIG. 5. a further situation in which mYc is negatively regulated by a kinase that is involved in the control of actin cytoskeleton organization is expression of the serine-threonine-specific In the upper part of the figure solid arrows denote events that are stimulated by MYC: exit from the stem-cell compartment, transit-amplifying-cell proliferation and terminal differentiation along the sebocyte and interfollicular epidermal (IFE) lineages. MYC antagonism by RAC1-PAK2 (p21-activated kinase 2) 42 and LRIG1 (leucine-rich repeats and immunoglobulin-like domains-containing protein) 13 is shown and results in inhibition of stem-cell proliferation (through LRIG1) and inhibition of both proliferation and terminal differentiation (through RAC1-PAK2). The lower part of the figure illustrates the transcription complexes that are involved in stimulating MISU (MYC-induced SUN-domaincontaining protein; also known as NSUN2) expression 14 and repressing expression of cell-adhesion and cytoskeleton genes 19 . MYC-mediated inhibition of cell adhesion is dependent on repression of gene expression through complex formation with MIZ1. By contrast, expression of MISU, which is required for MYC-induced stimulation of proliferation, is positively regulated by MYC. HF, hair follicle; SC, stem cell; SG, sebaceous gland; TA, transit amplifying cell. Nature Reviews | Cancer Inhibition of mYc by lImK1 is through inhibition of STaT3 (signal transducer and activator of transcription 3) phosphorylation. constitutive activation of cofilin or inhibition of rho kinase results in STaT3 phosphorylation and increased mYc levels. In the hyperproliferative lesions that are characteristic of psoriasis, there is downregulation of lImK1 and upregulation of mYc in the suprabasal epidermal layers 8 . The ability of mYc to decrease the expression of genes that encode proteins mediating cell adhesion and cytoskeletal assembly is observed in many cell types 47 , but the consequences are context dependent. In the epidermis, reduced cell adhesion functions as a terminal differentiation stimulus 41 , whereas in the mammary gland, mYcdependent downregulation of E-cadherin stimulates invasion 48 . mYc-induced differentiation of human embryonic stem cells occurs through integrin downregulation 49 and mYc induces haematopoietic stem cells to exit their niche by downregulation of adhesion factors such as α 6 integrin and N-cadherin 50 .
MYc-induced chromatin modifications
In addition to activating or repressing expression of specific genes, mYc has a range of effects on chromatin and basal transcription. mYc influences global chromatin structure 51, 52 and is required for the maintenance of active chromatin 53 (FIG. 6a) . It is therefore of interest to investigate whether epidermal stem cells can be distinguished on the basis of global histone modifications and whether these are altered by activation of mYc 54 . By labelling human and mouse epidermis with antibodies to different histone modifications, we found that compared to other cells in the basal layer of the epidermis, quiescent, nondividing, stem cells have high levels of trimethylation of histone h3 lysine 9 (h3K9me3), h4K20me3 and hypoacteylation of histone h4, and lack h4K20me1 (FIG. 6b) . This signature indicates that most of the chromatin in quiescent epidermal stem cells is silenced. activation of mYc by 4-ohT treatment of K14-mYc-Er mice results in profound changes in these histone modifications. histone h4 acetylation is increased and there is a transient increase in h4K20me1, indicating that activation of mYc induces histone modifications in epidermal stem cells that are associated with active chromatin (FIG. 6b) . one mechanism by which mYc directly induces an active chromatin state is by negatively regulating h3K4me3-dependent demethylases 55 . as IFE cells undergo terminal differentiation, h4K20me1 is replaced by h3K9me2 and h4K20me2, changes that are features of chromatin silencing 54 . So, surprisingly, stem cells and terminally differentiated cells have characteristics of silent heterochromatin, whereas transit amplifying cells have their chromatin in a more active state 54 . Do mYc-induced chromatin modifications contribute to the stimulation of terminal differentiation? The mYc-induced switch from h4K20me1 to h4K20me2 in epidermis is blocked by the hDac (histone deacetylase) inhibitor trichostatin a (TSa). TSa treatment of wild-type epidermis induces a strikingly similar phenotype to activation of mYc, and is characterized by increased proliferation, detachment of basal cells from the basement membrane and stimulation of IFE and sebaceous-gland differentiation 54 . When K14-mYc-Er mice are treated with 4-ohT and TSa the epidermal phenotype is even more severe than with either treatment alone. These results suggest that mYc-induced chromatin modifications have an important role in mYc-induced exit from the stem-cell compartment and subsequent differentiation 54 . however, one caveat is that the effects of TSa on cultured epidermal cells are somewhat different and do not correlate with the amount of acetylated and deacetylated histones on the promoters of the differentiation-associated genes 56 . , whereas MYC stimulates stem cells to become transit amplifying cells 17, 28, 29 . There is evidence for mutual antagonism between the effects of RAC1 and MYC: RAC1 negatively regulates MYC through PAK2 (p21-activated kinase 2) phosphorylation 42 ; MYC decreases expression of the α 6 β 4 integrin through a MIZ1-dependent mechanism 19 ; and α 6 β 4 can activate RAC1 (ReF. We conclude that the nuclei of quiescent epidermal stem cells are enriched for chromatin modifications that are largely associated with gene silencing, but when mYc is activated chromatin modifications are induced that correlate with active gene transcription. one possible explanation would be that mYc facilitates an open chromatin state that is permissive for global transcription-factor binding. This would explain why mYc can contribute to the induction of pluripotency in adult somatic stem cells, even though it is not obligatory for this process [57] [58] [59] .
Regulators of MYc
So far we have focused on the downstream effects of mYc activation. however, it is clear that mYc is itself regulated, both negatively and positively, by several other transcription factors. Two negative regulators, ovol1 and BlImP1 (B-lymphocyteinduced maturation protein 1), and one positive regulator, β-catenin, profoundly influence the behaviour of epidermal cells.
ovol1 is the mammalian homologue of the Drosophila melanogaster ovo gene, which has a role in patterning the larval cuticle. ovol1 is a zinc-finger-containing transcription factor that binds to the Myc promoter and represses transcription 60, 61 . ovol1 is expressed in the suprabasal differentiating cells of the IFE and hair follicle 60 and on deletion of Ovol1 mYc is upregulated in the suprabasal epidermal layers 61 .
Ovol1
-/-embryonic epidermis is characterized by increased proliferation 61 . In adult epidermis there is largely normal expression of terminal-differentiation markers in the IFE and hair follicle, but the hair shafts develop abnormal kinks and splits 60 . ovol1 is induced in response to TGFβ signalling and is a FoXo-dependent TGFβ response gene 62 . consistent with this, OVOL1 -/-keratinocytes in culture exhibit impaired growth arrest in response to TGFβ 61 . BlImP1 is a key transcriptional regulator of B-and T-lymphocyte differentiation 63 and, like ovol1, it binds to and negatively regulates the MYC promoter 64, 65 . BlImP1 is expressed in the differentiating cells of the IFE, hair follicle and sebaceous gland 65 , and also in a population of unipotent sebaceousgland progenitor cells 64 . Blimp1-null epidermis is characterized by increased mYc expression, increased proliferation and sebaceous-gland enlargement 64, 65 . Therefore, the downregulation of mYc that occurs during epidermal terminal differentiation correlates with upregulation of two transcriptional repressors of mYc, ovol1 and BlImP1.
Whereas the effects of BlImP1 and ovol1 in the epidermis have only recently been described, β-catenin is well known to have a key role in epidermal stem-cell renewal and lineage selection 1, 3 . MYC is a β-catenin target gene that mediates proliferation in response to Wnt activation in intestinal epithelium 66 . however, in the epidermis the populations that proliferate in response to mYc and β-catenin are different. β-catenin stimulates proliferation of cells at the base of growing hair follicles and causes local increases in proliferation at sites of ectopic hair-follicle formation 40 , whereas mYc stimulates proliferation primarily in the IFE and sebaceous gland 31 . In addition, the effects on epidermal lineage selection are quite different, with mYc promoting differentiation into IFE and sebaceous gland (FIG. 3) and β-catenin stimulating ectopic hair-follicle formation 40 . Even more striking is that overexpression of an N-terminally truncated form of lEF1 (lymphoid enhancer binding factor 1), which blocks β-catenin signalling, stimulates sebaceousgland and IFE differentiation 67, 68 , thereby resembling mYc.
The reasons why activating mYc and blocking β-catenin by expression of ∆NlEF1 produce similar results have yet to emerge. however, there are several observations that hint at complexity in the interaction between mYc and β-catenin. one is that JuP (junction plakoglobin), which like β-catenin is an armadillo-containing protein that is involved both in cell-cell adhesion and nuclear signalling, suppresses mYc expression in the skin 69 . another is that the DNa helicases pontin and reptin physically interact with mYc and are antagonistic regulators of Wnt signalling 70 . The effects of overexpressing these proteins in Xenopus laevis embryos are similar to the effects of overexpressing mYc, and embryonic 53, 75, 76 . Histones are shown as trimethylated (Me) in silent chromatin and acetylated (Ac) in active chromatin. b | Changes in histone methylation during the transition from stem cell (SC) to transit amplifying cell (TA) to terminally differentiated epidermal cell (TD) 54 . Levels of tri-(Me3), di-(Me2) and mono-(Me1) methylated histones are shown. DNMT3A, DNA methyltransferase 3A; HAT, histone acetyl transferase; HDAC, histone deacetylase; HP1, heterochromatin-like protein 1; MTase, methyltransferase.
lethality resulting from knockdown of pontin or reptin can be rescued by overexpressing mYc. They exert their mitogenic effect through the mYc-mIZ1 pathway 71 . The identification of factors that negatively regulate mYc in specific cells of the epidermis serves to illustrate the complexity of mYc function in the epidermis and provides a possible explanation for why mYc expression has different effects in different cell types.
MYc: dose, timing and context When is an oncogene not an oncogene? When it stimulates cells to differentiate. Studies of mYc function in the epidermis have revealed some of the ways in which mYc can stimulate differentiation but more remain to be discovered. Just as epidermal cells respond differently to different levels of β-catenin activation 40 , it is likely that the level and duration of mYc activation within the epidermis will have different effects. a further consideration is that the repertoire of mYc binding partners varies between cells; this might explain, for example, why the artificial mYc repressor omomyc, which competes with maX for binding to mYc, but does not block mYcdependent repression of gene expression, inhibits mYc-induced epidermal tumour formation while potentiating mYcdependent apoptosis 34 . Studies in D. melanogaster have revealed that cells expressing different levels of mYc communicate with one another by releasing soluble factors 72 , suggesting a cooperative mechanism that could contribute to growth regulation within the epidermis and other tissues. It will clearly be of great interest to examine how these issues affect mYc function in the epidermis.
For now, it seems reasonable to conclude that within the epidermis mYc can function both as an agent that promotes the differentiation of stem cells 28, 29 and as an oncogene 21, 33 . Squamous-cell carcinomas are characterized by multiple genetic and epigenetic changes 5 . We favour the idea that within a malignant epidermal cell the ability of mYc to promote differentiation might be abrogated by some of those changes. a specific example is that if a tumour has acquired an activating integrin mutation 73 some of the inhibitory effects of mYc on cell adhesion could be prevented, thereby over-riding the 'failsafe' differentiation response. a better understanding of these issues will lead to new approaches to targeting mYc in squamous-cell carcinoma.
